Pediatric patients with hidradenitis suppurativa have increased rates of various comorbidities, including anxiety and obesity.

The likelihood of reduced quality of life and high symptom burden in patients with psoriasis was similar across those with low, medium, and high BSA.

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

The FDA sent letters to companies selling products with concentrated 7-hydroxymitragynine, which is illegal to market.

Upadacitinib demonstrated greater clinical efficacy and a comparable safety profile to adalimumab for treating RA, regardless of patients’ baseline CV risks.

The eligibility criteria of trial populations are frequently inconsistent with those of the approved-label population.